Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 2/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.38 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.37 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL951750 | 1.00 | CHEK2 (0.47) | CHEK2GPR119USP30MEN1ALDH1A1 | |
| SCHEMBL950851 | 0.89 | GPR119 (0.57) | CHEK2GPR119USP30PDE4BALK | |
| SCHEMBL950850 | 0.89 | GPR119 (0.57) | CHEK2GPR119USP30PDE4BALK | |
| SCHEMBL951749 | 0.84 | GPR119 (0.50) | CHEK2GPR119USP30MEN1ALDH1A1 | |
| SCHEMBL31270132 | 0.82 | GPR119 (0.50) | CHEK2GPR119USP30MEN1ALDH1A1 | |
| SCHEMBL15888739 | 0.79 | GPR119 (0.61) | CHEK2GPR119ALDH1A1PDE4BTBK1 | |
| SCHEMBL14481755 | 0.78 | GPR119 (0.57) | CHEK2GPR119ALDH1A1ALK | |
| SCHEMBL14481757 | 0.78 | GPR119 (0.57) | CHEK2GPR119ALDH1A1ALK | |
| SCHEMBL21887529 | 0.77 | GPR119 (0.56) | GPR119USP30TBK1ALK | |
| SCHEMBL30140249 | 0.77 | GPR119 (0.49) | GPR119USP30TBK1ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021779-A1 | PROCESS FOR THE PREPARATION OF 6-SUBSTITUTED-1-(2H)-ISOQUINOLINONES | SANOFI-AVENTIS (FR) | 2011-01-27 | — | — | US | claimed |
| EP-2240441-A1 | PROCESS FOR THE PREPARATION OF 6-SUBSTITUTED-1-(2H)-ISOQUINOLINONES | Sanofi-Aventis (FR) | 2010-10-20 | — | — | EP | claimed |
| WO-2009080335-A1 | PROCESS FOR THE PREPARATION OF 6-SUBSTITUTED-1-(2H)-ISOQUINOLINONES | SANOFI-AVENTIS (FR) | 2009-07-02 | — | — | WO | claimed |
| US-8716481-B2 | Process for the preparation of 6-substituted-1-(2H)-isoquinolinones | SANOFI (FR) | 2014-05-06 | — | — | US | disclosed |
| US-20110021779-A1 | PROCESS FOR THE PREPARATION OF 6-SUBSTITUTED-1-(2H)-ISOQUINOLINONES | SANOFI-AVENTIS (FR) | 2011-01-27 | — | — | US | disclosed |
| EP-2240441-A1 | PROCESS FOR THE PREPARATION OF 6-SUBSTITUTED-1-(2H)-ISOQUINOLINONES | Sanofi-Aventis (FR) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009080335-A1 | PROCESS FOR THE PREPARATION OF 6-SUBSTITUTED-1-(2H)-ISOQUINOLINONES | SANOFI-AVENTIS (FR) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021779-A1 | PROCESS FOR THE PREPARATION OF 6-SUBSTITUTED-1-(2H)-ISOQUINOLINONES | CYP1B1, CYP1A1, NQO1 | CHEK2 2770/4885GPR119 3335/4885USP30 3268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.